News Pressure rises on Novo as Innovent drug tops Ozempic Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.
News ESMO: Lilly reveals scale of survival win with Verzenio Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.
News Lilly says oral GLP-1 could be 'foundational' diabetes drug Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.
News FDA clears Roche, Lilly Alzheimer's blood test A blood test developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer's more quickly has been approved by the FDA.
News After FDA exit, Peter Marks pops up at Lilly The ousted former director of CBER, Peter Marks, has joined Eli Lilly as head of molecular discovery and infectious disease research.
News GLP-1s from Novo, Lilly 'should be first-line in obesity' European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
